Symbols

TMDX

TransMedics Group·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TMDX

Transmedics Group, Inc.

A medical technology company that transforming organ transplant therapy for end-stage lung, heart, and liver failure

Industry

Healthcare Technology

Established Date

Listing Date

05/02/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

898

Fiscal Year Ends

12-31

Website

www.transmedics.com

Security Type

Common stock

Office address

200 Minuteman Road, Andover, Massachusetts 01810

Business

Introduction

TransMedics Group, Inc., was registered in August 1998. The company is a commercial-stage medical technology company that provides organ transplant treatment to patients with end-stage organ failure in multiple disease states. The company developed the catenary to replace the decades-old standard of care. The company's innovative catenary technology replicates many aspects of the natural living and functional environment of external human organs. OCS represents a change in approach that transplants preservation from a static state to a dynamic environment, enabling new functions, including organ optimization and evaluation.

Company Financials

EPS

TMDX has released its 2025 Q4 earnings. EPS was reported at 0.57, versus the expected 0.39, beating expectations. The chart below visualizes how TMDX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TMDX has released its 2025 Q4 earnings report, with revenue of 160.76M, reflecting a YoY change of 32.18%, and net profit of 105.38M, showing a YoY change of 1436.87%. The Sankey diagram below clearly presents TMDX's revenue sources and cost distribution.